Treatment with RvE1 was previously demonstrated to reduce the expression of NF-kB and COX-2 Our findings suggest that RvE1 treatment may reduce AgNP-induced inflammation in healthy and MetS models via regulation of COX-2 production of proinflammatory mediators. Here, NFKB1 is linked to metabolic syndrome.